Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Forma Therapeutics Holdings Inc (NQ: FMTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Oct 13, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Forma Therapeutics Holdings Inc

< Previous 1 2 Next >
Biotech Stocks Well-Positioned For The Fourth Quarter
The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far. 
Via Talk Markets
Novo Nordisk Touts Another Once-Weekly Insulin Icodec Win In Type 2 Diabetes
Via Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Top Russell 2000 Stocks: Trading Opportunities For Next Week - Sunday, Sept. 11
A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Here is a closer look at some Russell 2000 stock... 
Via Talk Markets
4 Analysts Have This to Say About Forma Therapeutics Hldgs
Within the last quarter, Forma Therapeutics Hldgs (NASDAQ:FMTX) has observed the following analyst ratings: 
Via Benzinga
Recap: Forma Therapeutics Q2 Earnings
  Forma Therapeutics Hldgs (NASDAQ:FMTX) reported its Q2 earnings results on Friday, August 5, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Read Why Forma Therapeutics' Current Price Level Is 'Attractive Entry Point'
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2022
  
Via Benzinga
This Analyst Predicts $700 For Broadcom, Plus RBC Capital Slashes PT On This Stock By 85%
Keybanc cut the price target for Broadcom Inc. (NASDAQ: AVGO) from $780 to $700. Broadcom shares rose 2.3% to $503.14 in pre-market trading. 
Via Benzinga
Dow Turns Higher; Gold Down 1%
U.S. stocks pared losses, with the Dow Jones turning higher toward the end of trading on Thursday. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
Recap: Forma Therapeutics Hldgs Q1 Earnings
Forma Therapeutics Hldgs (NASDAQ:FMTX) reported its Q1 earnings results on Friday, May 6, 2022 at 07:05 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Earnings Scheduled For March 1, 2022
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
Why Snap Shares Jumped 7%; Here Are 75 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Nasdaq Tumbles 250 Points; Crude Oil Falls Sharply
U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping over 250 points on Thursday 
Via Benzinga
Why Okta Is Trading Lower By Over 32%, Here Are 58 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 94.4% to $27.24. ShiftPixy announced a 1-for-100 reverse stock split. 
Via Benzinga
Novo Nordisk Jumps Into Sickle Cell Fray With $1.1 Billion Forma Therapeutics Buyout
The deal helps beef up Novo's early-stage efforts in sickle cell disease. 
Via Investor's Business Daily
Nutanix, Five Below And Some Other Big Stocks Moving Higher On Thursday
  Forma Therapeutics Holdings, Inc. (NASDAQ: FMTX) jumped 48.5% to $19.90 after Novo Nordisk announced it will acquire the company for $20 per share in cash. 
Via Benzinga
Guardforce AI (GFAI) Stock Gets a Boost From New Exec Team
Guardforce AI (GFAI) stock is climbing higher on Thursday after announcing a new executive team that will lead the company. 
Via InvestorPlace
Forma Therapeutics (FMTX) Stock Soars on Novo Nordisk Acquisition News
There's a major pharmaceutical market deal afoot -- and it's worth over $1 billion -- so FMTX stock is heading higher on the news. 
Via InvestorPlace
After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal
Via Benzinga
Earnings Outlook For Forma Therapeutics Hldgs
Forma Therapeutics Hldgs (NASDAQ:FMTX) is set to give its latest quarterly earnings report on Friday, 2022-08-05. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Earnings Scheduled For August 5, 2022
Companies Reporting Before The Bell • Reservoir Media (NASDAQ:RSVR) is projected to report quarterly loss at $0.05 per share on revenue of $18.19 million. 
Via Benzinga
Rigel Pharma Expands Blood Cancer Portfolio With Forma Therapeutics Licensing Pact
Via Benzinga
Earnings Scheduled For May 6, 2022
Companies Reporting Before The Bell • Brookfield Renewable (NYSE:BEP) is expected to report quarterly loss at $0.02 per share on revenue of $1.27 billion. 
Via Benzinga
Preview: Forma Therapeutics Hldgs's Earnings
Forma Therapeutics Hldgs (NASDAQ:FMTX) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
Forma Therapeutics: Q4 Earnings Insights
Forma Therapeutics Hldgs (NASDAQ:FMTX) reported its Q4 earnings results on Tuesday, March 1, 2022 at 07:05 AM. Here's what investors need to know about the announcement... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus J&J to Separate Its Consumer Health Business Into a New Publicly Traded... 
Via Benzinga
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.